"Peer Baneke is the Chief Executive Officer of the Multiple Sclerosis International Federation (MSIF) and a permanent observer of the European Multiple Sclerosis Platform (EMSP). Peer grew up in Amsterdam. His father had MS. He moved to London and worked for 20 years for human rights globally and refugee protection throughout the European Union. In 2007, he became Chief Executive Officer of the Multiple Sclerosis International Federation (MSIF). He has been playing an important role at the Executive Committee of the European Multiple Sclerosis Platform (EMSP) as permanent observer in and contributor to all its meetings. Mr. Baneke thinks the EMSP is an essential player in the global MS movement."
Giancarlo Comi is Professor of Neurology, Chairman of the Department of Neurology, and Director of the Institute of Experimental Neurology at Vita-Salute San Raffaele University, Milan, Italy. He is also President of the European Charcot Foundation (ECF), a member of the Board of Administration of the Italian Multiple Sclerosis Foundation and of the Scientific Committee of Associazione Italiana Sclerosi Multipla, Co-Chair of the Scientific Steering Committee of the Progressive MS Alliance, and a fellow of the European Academy of Neurology (EAN). He has served as a past president of the European Neurology Society, the Italian Society of Clinical Neurophysiology, and the Italian Society of Neurology.
In recent years, Professor Comi has received the ‘Gh. Marinescu’ honorary award from the Romanian Society of Neurology, and has been awarded honorary memberships of the Russian Neurological Academic Society, the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), the European Neurological Society (ENS) and the Sociedad Espanola de Neurologia. He also received the Charcot Award for MS Research from the MS International Federation (MSIF) in 2015. In the past year Professor Comi was awarded the Gold Medal of ‘Benemeranza Civica’ from the City of Milan and has been recently conferred the honor of merit as Official by the President of Italy.
Prof. Comi has authored and co-authored more than 1000 articles in peer-reviewed journals, and edited several books, with an h-index of 100. He has been the invited speaker for more than 450 conferences, both nationally and internationally. He sits on the executive boards of various scientific associations and on the editorial boards of Clinical Investigation, European Journal of Neurology and Multiple Sclerosis. He is also the Associate Editor of the Neurological Sciences.
Nicholas (Nick) Cummins is a lecturer in AI for speech analysis for health at the Department of Biostatistics and Health Informatics at King’s College London. Nick’s current research interests include speech processing, affective computing and multisensory signal analysis. He is fascinated by the application of machine learning techniques to improve our understanding of different health conditions and mental health disorders in particular. Nick is actively involved in RADAR-CNS project in which he assists in the management of Work Package 8: Data Analysis & Biosignatures. Nick was awarded his PhD in electrical engineering from UNSW Australia in February 2016 for his thesis ‘Automatic assessment of depression from speech: paralinguistic analysis, modelling and machine learning’. After completing his PhD, he was a postdoctoral researcher at the Chair of Complex and Intelligent Systems at the University of Passau, Germany. Most recently, he was a habilitation candidate at the Chair of Embedded Intelligence for Health Care and Wellbeing at the University of Augsburg, also in Germany. During his time in Germany, he was involved in the DE-ENIGMA, RADAR-CNS, TAPAS and sustAGE Horizon 2020 projects. He also wrote and delivered courses in speech pathology, deep learning and intelligent signal analysis in medicine.
Marcus D Souza is the head of Neurostatus-UHB and an Attending Physician in the Department of Neurology of the University Hospital Basel. Since 02/2018 he is also a post-doc researcher at the NCRC, Charité Berlin. He studied medicine in Cologne (DE), New York City (USA) and Bochum (DE) and completed his training in Neurology in Bochum (DE) and Basel (CH). For more than 10 years he is interested in the improvement of clinical scales and measurement tools for quantifying disability in Multiple Sclerosis (MS). He has undertaken various research projects, including a collaborative project with Microsoft Research (Cambridge, UK), focusing on the development of a Kinect-based motion-capturing device for a quantitative analysis of disability in MS. His recent research focuses on the development of progression marker for MS based on the Neurostatus-EDSS. Moreover, in the Charité Berlin he works on the development of a disability scale and attack criteria for neuromyelitis optica spectrum disorders (NMOSD).
Maarten De Vos has a joint appointment as Associate Professor in the Departments of Engineering and Medicine at KU Leuven after being Associate Professor at the University of Oxford, United Kingdom, and Junior Professor at the University of Oldenburg, Germany. He obtained an MSc (2005) and PhD (2009) in Electrical Engineering from KU Leuven, Belgium. His academic work focuses on AI for health, innovative biomedical monitoring and signal analysis for daily life applications, in particular the derivation of personalised biosignatures of patient health from data acquired via wearable sensors and the incorporation of smart analytics into unobtrusive systems. His pioneering research in the field of mobile real-life brain-monitoring has won several innovation prices, among which the prestigious Mobile Brain Body monitoring prize in 2017. In 2019, he was awarded the Martin Black Prize for the best paper in Physiological Measurements. He has a strong interest in translational research and co-founded Circadian Therapeutics with the aim to bring innovative home-monitoring solutions to people suffering from sleep and circadian disorders. He has been guest editor for International Journal of Clinical Neurophysiology and Physiological Measurements. To date, he has (co-)supervised and supervised 10 PhD students to completion.
Arie R. Gafson is an academic researcher from Imperial College London. The author has contributed to research in topic(s): Multiple sclerosis & Natalizumab. The author has an hindex of 7, co-authored 12 publication(s) receiving 212 citation(s). Previous affiliations of Arie R. Gafson include Queen Mary University of London & University College London.
Gavin Giovannoni was appointed to the Chair of Neurology, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London in November 2006. He did his undergraduate medical training at Wits, where he graduated cum laude in 1987. He moved to the Institute of Neurology, UCL, Queen Square, London in 1993 after completing his specialist training in neurology in South Africa. After three years as a clinical research fellow and two years as the Scarfe Lecturer, he was awarded a PhD in immunology from the University of London in 1998. He was appointed as a Clinical Senior Lecturer, Royal Free and University College Medical School, in 1998 and moved back to Queen Square in 1999. He was made a Reader in Neuroimmunology in 2004. His clinical interests are multiple sclerosis and other inflammatory disorders of the central nervous system. He is particularly interested in clinical issues related to optimising MS disease-modifying therapies. Professor Giovannoni's current research is focused on Epstein Barr virus as a possible cause of multiple sclerosis (MS), MS-related neurodegeneration, MS biomarker discovery, MS clinical outcome measures, MS clinical trials and immune tolerance strategies. He has recently become the co-director of the Preventive Neurology Unit, Wolfson Institute of Population Health.
Asieh Golozar is Vice President, Global head of Data Science at Odysseus Data Services, at Odysseus Data Services, where she leads a team of data scientists, epidemiologists and bioinformaticians focusing on epidemiological research and development and application of advanced and innovative analytics across a large global network of observational data. Asieh is also professor of the practice and director of clinical research at the OHDSI Center in Northeastern university leading the reproducibility service at the center. Since 2018, Asieh has led the OHDSI Oncology Working Group, endeavoring to extend the OMOP CDM to support oncology use cases and advance large-scale observational oncology research. Asieh is a physican epidemiologist with more than 20 years of experience in life science research and medicine in industry, academia, and government settings. She holds a PhD in epidemiology and a Master of Health Sciences in biostatistics from the Johns Hopkins University School of Public Health, supported by a postdoctoral research fellowship award with the National Cancer Institute’s Division of Cancer Epidemiology and Genetics. She earned her medical degree from the Tehran University of Medical Sciences. After receiving her PhD, she joined the faculty at the Department of Epidemiology, JHU School of Public Health focusing on cancer and diabetes epidemiology and applying evidence-based findings to strengthen public heath infrastructure and policies. She then joined the pharmaceutical industry where she worked as pharmacoepidemiology therapeutic area lead and expert at Regeneron Pharmaceuticals, AstraZeneca and Bayer and led and contributed to the integration of effective and efficient observational research strategy into the research and development, clinical development, and life cycle management in different therapeutic areas specifically oncology.
Cristina Granziera obtained a MD at Padova University Medical School (Padova, Italy) in 2001, a PhD in Neuroscience at Lausanne University (Lausanne, Switzerland) in 2007 and the Swiss Neurology board in 2010. In 2011, she was appointed as lecturer at University of Lausanne, where she was promoted to senior lecturer in 2014. In 2015, she joined the Massachusetts General Hospital (MGH) and Harvard Medical school (Boston, MA, USA) as assistant professor in Radiology and assistant in Biomedical Engineering. Currently she works as senior consultant neurology at University Hospital of Basel, as professor in neurology and biomedical engineering at University of Basel and she is part of the steering committee of the “Research Center for Neuroscience and Neuroimmunology (RC2NB)” in Basel. The focus of Dr Granziera’s research is the investigation of the pathogenesis of neuroinflammatory and cerebrovascular diseases - such as multiple sclerosis, neuroHIV, migraine and stroke- using state-of-the art neuroimaging methods. She is particularly interested in the combination of multiple quantitative MRI contrasts to achieve the highest sensitivity and specificity to brain tissue pathology, as well as in multi-modal approaches like MRI-PET. Her goal is to propose new models of disease impact and innovative tools to study disease evolution, by using the combined information of neuroimaging data, biological and clinical markers of disease. To pursue her research, Dr Granziera has been awarded numerous research grants including support from the Swiss National Research Fund (Switzerland) and the National Institute of Health (USA). She was also awarded the prestigious Translational Research Award of Lausanne University in 2010 and the Innovation–Award of MGH in 2017. Currently, she serves in the scientific advisory boards of numerous scientific societies and healthcare companies.
Dr Hillert is a
professor of neurology at Karolinska Institutet in Stockholm Sweden and
consultant in neurology at the Karolinska Univeristy Hospital since 2001 where
he also holds the position as Director of research and Education. Dr Hillert’s
special interest, both clinically and in research, is multiple sclerosis (MS).
In 1995 he started what in 2000 became the national Swedish Multiple Sclerosis
Registry, SMSreg, one of the leading MS regsitries witt currently over 80 % of
prevalent MS patients in Sweden assessed, at an average for over 7 years.
Starting in the late 1980:ies Dr Hillert focused on the genetics of MS and
contributed to what eventually became a success story with over 200 MS loci
discovered through the joint efforts of the International MS Genetics
Consortium. In recent years, his research efforts have moved into other aspects
of MS epidemiology including pharmacoepidemiology and health economics and
outcomes research, in MS. An important aim for Dr Hillert is the development of
registries within MS and neurology in general and international collaboration
between such registries and data bases, such as in the Big MS Data initiative.
Dr Hillert has published over 260 original papers.
COI form
Jana was diagnosed with MS when she was 24. Since 2015 she has been a member of European Multiple Sclerosis Platform’s (EMSP) young people’s network and from 2015 to 2017 she was the young people’s representative at the organization’s Executive Committee. She joined the Civic Association SMS – an association of and for young people with MS in the Czech Republic – in 2013 and led the organization between 2014 and 2016. She currently works for The European Multiple Sclerosis Platform (EMSP). Her strategic management and planning experience, networking and communication skills as well as her active involvement as young advocate made Jana a recognized MS ambassador both at European and national level.
Matthew Hotopf is Vice Dean of Research at the Institute of Psychiatry Psychology and Neuroscience. He is a Professor of General Hospital Psychiatry, a consultant liaison psychiatrist and is also Director of the South London and Maudsley NHS Foundation Trust National Institute of Health Research Biomedical Research Centre (BRC). His main area of research is in the grey area between medicine and psychiatry, exploring the interaction between mental and physical health.
"Originally trained in Theoretical Physics and Philosophy in the 1990s, Dr. Jirsa has made contributions to the understanding of how network structure constrains the emergence of functional dynamics using methods from nonlinear dynamic system theory and computational neuroscience. Dr. Jirsa has been awarded several international and national awards for his research including the Francois Erbsmann Prize in 2001, NASPSPA Early Career Distinguished Scholar Award in 2004, and Grand Prix de Recherche de Provence in 2018. He serves on various Editorial Boards and has published more than 150 scientific articles and book chapters, as well as co-edited several books including the Handbook of Brain Connectivity. Dr. Jirsa is one of the Lead Scientists in the Human Brain Project and The Virtual Brain. He has been appointed Chief Science Officer of EBRAINS on June 28, 2022."
Professor Tomas Kalincik is Dame Kate Campbell Professorial Fellow, the head of the Clinical Outcomes Research (CORe) Unit at the University of Melbourne and of the MS Centre at the Royal Melbourne Hospital. Tomas trained as a neurologist in the Czech Republic and he holds a degree in medicine/surgery from Charles University in Prague, PhD in neuroscience from the University of New South Wales and a Postgraduate Certificate of Biostatistics from the University of Melbourne. Together with his research group, CORe, Tomas specialises in analytics of observational data in neurology. He is the chair of the Scientific Leadership Group of the global MSBase collaboration . He has launched CORe Advanced Statistics Course, an international course held in Melbourne, endorsed by the European Committee for Treatment and Research in Multiple Sclerosis, which teaches advanced statistical methods to clinical researchers in neurology. He has led a number of international collaborative research projects and his work has influenced clinical practice in treatment of multiple sclerosis - including discoveries in comparative treatment effectiveness, management of treatment failure and individual treatment response. Tomas and CORe publish in leading medical and neurology journals, including JAMA, The Lancet Neurology, Nature Reviews Neurology, JAMA Neurology, Brain and Neurology. His main research interests span treatment and outcomes of MS and neuromyelitis optica, individualised therapy, prognostics (including emerging biomarkers), causal inference, epidemiology and utility of volumetric MRI.
"Letizia Leocani is Associate professor of Neurology at Vita-Salute San Raffaele University, Neurologist in the Neurorehabilitation Unit of the Neurological Dep.t and supervisor of the Experimental neurophysiology Unit and of Magnetic IntraCerebral Stimulation (MagICSI) center - Institute of Experimental Neurology, IRCCS Ospedale San Raffaele. After her medical degree, she obtained a PhD in Human Physiology and Neurology specialty and she has been Research Fellow at the Human Motor Control Section of the National Institutes of Health in Bethesda-USA. She is Co-Chair of the Clinical Neurophysiology scientific panel of the European Academy of Neurology. Her fields of interest involve translational validation of electrophysiological (advanced EEG analysis, evoked and cognitive potentials) and structural (optical coherence tomography - OCT) markers of diseases of the central nervous system and of treatment strategies using non invasive brain stimulation to potentiate the effects of drugs and neurorehabilitation."
"Yves Moreau is a Professor of Engineering at the University of Leuven, Belgium. His research focuses on AI algorithms and software platforms for the integration of complex data in clinical genomics and drug discovery: (1) federated analysis of real-world clinical and genomic data, (2) data fusion algorithms for the identification of pathogenic genetic variation in rare genetic disorders and liquid biopsies, and (3) data fusion for drug discovery and drug design. At the algorithmic level, he focuses on the development of novel AI methods, such as deep learning and Bayesian matrix factorization, for the fusion of heterogeneous sparsely-observed data; and on privacy-preserving implementations of such methods. He is a fellow of the International Society for Computational Biology and a member of its board of directors. He co-chaired the joint Intelligent Systems in Molecular Biology and European Conference on Computational Biology (ISMB/ECCB 2017) conference and chaired the ECCB 2010 conference. He is a member of the steering committees of the European Conference on Computational Biology and Machine Learning in Systems Biology conference series. From 2011 till 2018, he coordinated the SymBioSys Center for Computational Systems Biology, a large interfaculty effort at the University of Leuven to better understand the link between genomic variation and human genetic disorders through omics data integration and next-generation sequencing. From 2011 to 2015, he was also program director of the Master of Bioinformatics, an interdisciplinary program in English with enrollment of over 50 students, two thirds of whom from abroad. He is a tech innovator who co-founded two spin-offs of the University of Leuven. One of them, Cartagenia, now part of Agilent Technologies, is a leader in ICT solutions for NGS in clinical genomics. He is also a concerned scientist critically reflecting on how information technology and artificial intelligence are transforming society and how to ensure this transformation is for the common good."
James N’Dow is Director of the Academic Urology Unit since its establishment in 2001. His research activity spans across evidence synthesis, trials, guideline development, implementation science and the use of big data to complement traditional trial data. He has consistently secured significant funding for research totalling over £43 million over the past 20 years; including being the Coordinator of two large EU IMI funded big data for better outcomes projects. He is Coordinator of the €12M EU IMI funded 5 year project on prostate cancer big data (https://prostate-pioneer.eu/), a large European Multidisciplinary Consortium of 35 partners from 9 countries to harness the power of Big data to inform clinical practice recommendations. He recently successfully coordinated a second €21.3M EU IMI funded large consortium of 36 partners called OPTIMA researching three solid cancers (Prostate, Breast and Lung cancers). He was Coordinating Editor of the Cochrane Incontinence Review Group and has a track record in delivering NIHR funded national trials in urology. He is co-lead for the recently funded British Association of Urological Surgeons TUF Trials Unit awarded to CHaRT. Appointed Chair of European Association of Urology Guideline Office Board in 2014. Under his leadership, the EAU Guidelines have become the most comprehensive and trusted urological surgical practice guidelines globally, endorsed by 75 countries. Co-founder and MD of UCAN. UCAN has led 3 fundraising campaigns over the past 15 years, raising over £7 million in philanthropic contributions (cash and in-kind) galvanising the support of the local business community. UCAN funded the opening of the first Urological Cancer Care Centre in Scotland, brought the first robotics surgical system to Scotland as well as contributing £2,517,000 to University of Aberdeen for urological cancer related research. He is also Founder and trustee for Horizons Trust UK charitable trust.
Tina Parciak has a background in Medical Informatics and has been part of the MS Data Alliance since its very beginning, bringing the topic of harmonisation of real-world data in MS forward. Within her current PhD studies at the Biomedical Research Institute and Data Science Institute at UHasselt, she is developing and orchestrating new technologies and strategies for harmonisation for real-world MS data sources. One of her research interests lies in the adaptability of the OMOP common data model (OHDSI) for real-world data coming from registries. She is the lead of the OHDSI Registry workgroup.
Liesbet M. Peeters is one of the main initiators and coordinator of the MS Data Alliance initiative. She has a strong personal mission to transform the mostly population based management of multiple sclerosis (MS) of today in to an individualized, personalized and precision level management. She believes that the key to achieve this next level of MS management is “FAIR” data (=Findable, Accessible, Interoperable and Re-usable). Her research focusses on tackling following two main challenges: 1° developing IT tools to find and access real-world datasets and 2° developing analytical tools for optimal mining of real-world dataset. She has been invited to speak at several international conferences to summarize her data sharing vision. She is a member of the core group of the European Patient Forum initiative “Data Saves Lives”. Currently, she is a data scientist researcher at the Biomedical Research Institute of Hasselt University (Belgium). In 2013, she finished her PhD in Bio-Engineering Sciences at the KULeuven in Belgium. She has expertise in molecular genetic- and immunological techniques as well as quantitative genetic analysis. She is familiar with statistical programs, several data management software and has experience in Bio-informatics.
Ashkan Pirmani is a double degree PhD student of KU Leuven’s STADIUS/ESAT lab and the Biomedical data science research group of Hasselt University in Belgium. His research focuses on federated artificial intelligence in big data and healthcare. He is part of the operational team of the MSDA. He contributes to the infrastructure design of the MSDA toolkit. Ashkan was the lead architect of the federated pipeline in the Global Data Sharing Initiative (GDSI). His other research interests are Machine Learning, Collaborative Learning, Decentralization, Containerization, and Dashboard Design, with a keen interest in MLOps.
He is specialized in network neuroscience in multiple sclerosis (MS), using advanced imaging methods to study clinical progression. Imaging tools he uses to study brain networks and connectivity are based on functional MRI, magnetoencephalography, diffusion tensor imaging and atrophy measures. Apart from MS, he also studies these same aspects in Parkinson disease.
Maria Trojano is
Professor of Neurology at the University of Bari, Italy andis currently Head of the Department ofBasic Medical Sciences, Neurosciences and
Sense Organs and Director ofthe Neurology
and Neurophysiopathology Units at the same University.
Professor Trojano was
President (2012-2014) of the European Committee for Treatment and Research in
Multiple Sclerosis(ECTRIMS). She is
Honorary Member of ECTRIMS. She is currently Member of the International
Advisory Committee on Clinical Trials in MS, under the sponsorship of the US
National MS Society and ECTRIMS.Since 2000
she is Chair of the Italian Multiple Sclerosis Registry. She is involved in a number
of Advisory Committees on clinical trials of new agents in MS.She
was member of the Education committee of theEuropean Academy of Neurology (EAN) and of Medical
and Scientific Advisory Board of Multiple Sclerosis International Federation
(MSIF).
She is active in
the design, implementation and analysis of phase IV clinical trials in MS and
conducts basic and applied research in Neuroepidemiology and Neurochemistry/Neuroimmunology.
She has published
over 300 original contributions in the MS field on international journals and
has authored a large number of book chapters.
Prof. dr. Bernard M.J. Uitdehaag (1958) studied medicine in Nijmegen and was trained in neurology in Amsterdam. In Amsterdam he was also trained in epidemiology. He is involved in MS research since 1985 and did his PhD in MS research in 1998. In 2009 he became a professor of neuro-epidemiology and in 2010 chair of the department of Epidemiology and Biostatistics in the VU University Medical Center (VUmc) in Amsterdam. In 2013 he became professor of Neurology and chair of the Department of Neurology of the VUmc in Amsterdam. In 2013 he also became Director of the MS Center Amsterdam. Between 2006 and 2014 he was member of the Netherlands Society of Neurology, being president from 2011 until 2014. In 2019 he also became chair of the Department of Neurology of the Academic Medical Center in Amsterdam. He is now chair of the department of Neurology of the Amsterdam University Medical Centers, a merger of both University Medical Centers in Amsterdam. He (co-)authored around 400 scientific papers.
"Wouter Van den Bosch is Program Manager & Cluster Lead Public Health at imec. Together with a great and capable team of innovation managers, project leads and developers, the Public Health cluster aims to drive digital transformation in the Flemish health scene & explore how technology can be used to create new insights in personalised and predictive health pathways. In the coming years, our focus will go towards building an Open Health Data Space, helping to unlock health data for research, innovation, care and policy. Wouter is a seasoned technologist with a passion for innovation, disruption and new technology applied well. In 2016 Wouter co-founded KnowledgeFlow.io, in order to help organisations overcome their current issues with knowledge management and essentially make knowledge usable on the workfloor. Before, Wouter worked as a researcher & project manager on ICT Innovation at Thomas More and helped both SME's as well as startups in the design of their innovations. Specialties: Data Spaces, Program Management, Digital Transformation in Health, Solution Design, Product Management, Project Management, Software Prototyping Methodology, Agile SCRUM, Living Labs Methodology, User Research, Innovation Research, Knowledge Management."
Wim Van Hecke is an academic engineer by training, holding master's degrees in applied biomedical engineering, physics, and neuroimaging. He obtained his PhD in medical sciences at the Antwerp University Hospital. Wim is the author of more than 250 scientific publications and the editor of a clinical neuroimaging handbook. He’s also a visiting professor at the University of Brussels. In addition, Wim Van Hecke is the founder and CEO of icometrix, a Belgian spin-off company focusing on developing digital health solutions to impact personalized care and medicine for people with neurological conditions, specifically Multiple Sclerosis.
Patrick Vermersch studied medicine at the University Hospital in Lille,
where he graduated in neurology. He then completed his education in more basic
research fields, mainly in cellular biology between 1990 and 1994 with a PhD
focused on biochemical abnormalities associated with Alzheimer’s and other
neurodegenerative diseases. He has also conducted research related to the
characterisations of post-transcriptional anomalies of Tau proteins. His
research interests then turned to multiple sclerosis (MS).
Prof. Vermersch is head of one of the departments of neurology at the
University of Lille, which
deals with MS and other neuroinflammatory diseases. The department’s
principal scientic interests
are neuroimmunology and markers of disease evolution.
Prof. Vermersch is currently vice-president of the University of Lille,
with the responsabilities of research in life sciences and health. In the year
2000, he created with colleagues the first MS network in northern France to
improve both care and research into MS. His current areas of interest are
prognostic markers of MS and neuroimmunology in general. He participates in
many therapeutic protocols on MS. He has published approximately 380 scientific
papers as author or co-author.
"Steven is a seasoned executive with more than 25 years of experience in different sectors. He worked in telecoms, space, media, advertising, logistics and healthcare. Throughout a career that started as a scientist and evolved into technical (software), management and even marketing and sales roles, the common thread has been introducing and applying new technologies in the market. Steven has taken leading roles in several internal start-ups in large companies and has done a MBO of a company in France. Recently he has been involved in applying his experience in digital transformation and data projects in several SME’s in Belgium."
Henry is currently Assistant Professor and Deputy Head of The D-Lab, in the dpt. of Precision Medicine at Maastricht University. Holding a PhD in astrophysics he now employs machine learning techniques and advanced quantitative image analysis methods to bring precision medicine closer to clinical implementation www.radiomics.world. Currently he is working on dozens of projects focused on finding prognostic and diagnostic imaging biomarkers related to diseases such as cancer, diabetes, Alzheimer's, and stroke. He also organizes the international course AI 4 Imaging.
Tjalf Ziemssen, MD, is Professor of Clinical Neuroscience in the Department of Neurology, Head of the Multiple Sclerosis Center and Neuroimmunological Laboratory, and Director of the Division of Neurometabolism at University Clinic Carl-Gustav Carus in Dresden, Germany. He earned his medical degree from the University of Bochum, Germany, and completed his neurology residency from University Hospital of Dresden, and neurobiology fellowship from Max-Planck-Institute of Neurobiology in Martinsried, Germany. His research is focused on exploring the complex interaction between the neuroendocrinology system and the immune system and psychiatric symptoms, with a particular emphasis on stress in patients with obesity and depression and its pathologic influence on cardiovascular function using animal experimental and clinical approaches. Dr Ziemssen has authored several articles that have been published in peer-reviewed journals including BMC Neurology, Heart Vessels, Psychoneuroendocrinology, and Annals of Neurology. He is a member of the German Neurological Society, European Neurological Society, and American Academy of Neurology.
